US-listed company Sonnet BioTherapeutics postpones merger vote to December 2
Foresight News reported that the US-listed company Sonnet BioTherapeutics has postponed its merger vote to December 2. Previously, it was reported that Sonnet BioTherapeutics would merge with Rorschach I LLC to form Hyperliquid Strategies and advance the HYPE reserve strategy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SuiGame completes major upgrade, officially rebrands as PumpGame, and launches on BNB Chain ecosystem
BOB: Community sale totals $4.2 million, with 2% of the 2,133 participants purchasing BOB tokens
89,200 SOL transferred to an exchange, worth approximately $125 million
Orderly Network launches Kronos QLS Vault
Trending news
MoreCrypto prices
More
